Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 WuXi PharmaTech Acquires XenoBiotic Labs | Contract Pharma

What are you searching for?

Sign in
Breaking News

WuXi PharmaTech Acquires XenoBiotic Labs

Expands lab testing division and presence in North America

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

WuXi PharmaTech (Cayman) Inc. has acquired XenoBiotic Laboratories, Inc. (XBL), a provider of bioanalytical, drug metabolism, and pharmacokinetic services to the pharmaceutical, animal health, and agrochemical industries. Financial terms were not disclosed. 
 
The acquisition expands WuXi’s Lab Testing Division in bioanalytical and DMPK/ADME services, specifically for radio-labeled compounds, expands LTD’s presence in North America, and provides access to new agricultural and animal health customers.
 
XBL has 150 employees and operates a 45,000-sq.-ft. research center in Plainsboro, NJ, and a 36,000-sq.-ft. facility in Nanjing, China. The company is FDA- and USDA-registered, New Jersey-licensed for work with radioisotopes, USDEA-licensed for conducting research with Schedule 1-5 controlled substances, and AAALAC-accredited.
 
“My colleagues and I are very excited to join WuXi, a global leader in providing drug discovery and development services to the global biopharmaceutical industry,” said Dr. Jinn Wu, president and chief executive officer of XBL, who has been appointed vice president and chief scientific officer of LTD. “We will continue to provide our services to our current clients while also offering expanded services to WuXi’s clients.”
 
“We are very pleased to have XBL join the WuXi team,” said Dr. Ge Li, chairman and chief executive officer of WuXi. “Dr. Wu has spent the past 27 years building a solid organization and reputation within the industry. This business combination is an important step in WuXi’s development of a comprehensive, integrated platform of R&D services to help our customers discover and develop drugs more efficiently and cost-effectively.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics